AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...
Investor's Business Daily on MSN3d
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. The results showed promise again rival drugs from Merck and NewAmsterdam Pharma, but AstraZeneca stock fell in line ...
AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...
AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...
On The Readout LOUD podcast, STAT reporters talk about new FDA commissioner Marty Makary's first week amid a swirl of layoffs ...
The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...
AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Subscribe here to receive future editions. The race to develop more convenient versions of drugs that lower cholesterol is heating up after AstraZeneca released encouraging new data on an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback